Contact – +1-276-477-5910
Email – [email protected]

Home >> Latest Reports

LATEST REPORTS

PRESS RELEASES

The 2023-2028 World Outlook for Anti-Migraine Drugs

This study covers the world outlook for anti-migraine drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the r...

5/10/2022 | anti-migraine drugs

The 2023-2028 World Outlook for Anti-Hepatitis Drugs and Vaccines

This study covers the world outlook for anti-hepatitis drugs and vaccines across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the count...

5/10/2022 | anti-hepatitis drugs and vaccines

The 2023-2028 World Outlook for Anti-Fog Lidding Films

This study covers the world outlook for anti-fog lidding films across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of th...

5/10/2022 | hypercholesterolemia drugs

The 2023-2028 World Outlook for Anti-Arthritic Drugs

This study covers the world outlook for anti-arthritic drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the ...

5/10/2022 | anti-arthritic drugs

The 2023-2028 World Outlook for Anesthesia Drugs

This study covers the world outlook for anesthesia drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the regi...

5/10/2022 | anesthesia drugs

The 2023-2028 World Outlook for Anemia Drugs

This study covers the world outlook for anemia drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, ...

5/10/2022 | anemia drugs

The 2023-2028 World Outlook for Allergy Drugs

This study covers the world outlook for allergy drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region,...

5/10/2022 | allergy drugs

The 2023-2028 World Outlook for Active Barrier Systems

This study covers the world outlook for active barrier systems across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of th...

5/10/2022 | ovarian cancer drugs

The 2023-2028 World Outlook for Acoustic Sensors

This study covers the world outlook for acoustic sensors across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the regi...

5/10/2022 | kidney cancer-treating drugs

Antibody Drug Conjugate Market Research: Global Status & Forecast by Geography, Type & Application (2017-2027)

According to 99Strategy, the Global Antibody Drug Conjugate Market is estimated to reach xxx million USD in 2021 and projected to grow at the CAGR of xx% during the 2022-2027. The report analyses the global Antibody Drug Conjugate market, the market size and growth, as well as the major market parti...

10/28/2021 | Drugs

First
Previous
1
2
3
4
5
6
7
8
9
10
Next

This study covers the world outlook for anti-migraine drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anti-migraine drugs as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Alder BioPharmaceuticals, Allergan, Amgen, Biohaven Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Kowa Pharmaceuticals America, Merck & Company, Novartis, Otsuka Pharmaceutical Company, Pfizer, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for anti-hepatitis drugs and vaccines across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anti-hepatitis drugs and vaccines as including all commonly understood products falling within this broad category, such as canned, fresh, reconstituted, and frozen juice derived from apples, oranges, bananas, grapefruit, strawberries, papayas, pineapples, and other fruits including juices containing mixed fruits and which may contain added ingredients, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Merck, and Vertex Pharmaceuticals. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for anti-fog lidding films across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anti-fog lidding films as including all commonly understood products falling within this broad category, such as systems providing quantitative and qualitative information analytics technology for clinical, agricultural, and environmental industries and other applications that require use of electrochemical, optical, thermal, and piezoelectric biochemical sensors, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include American Packaging, Bemis Company, Berry Global, CONSTANTIA, Cosmo Films, Coveris, Effegidi International, FLAIR Flexible Packaging, Flexopack, Hypac Packaging PTE, Linpac Packaging, Mondi, PLASTOPIL, ProAmpac, Rockwell Solutions, Ltd., RPC bpi group, Sealed Air, Toray Plastics, Transcendia, Uflex, and Winpak. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for anti-arthritic drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anti-arthritic drugs as including all commonly understood products falling within this broad category, such as functional additives for plastic packaging and barrier coatings for plastic packaging, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Amgen, Eli Lilly and Company, F. Hoffmann-La Roche, Johnson & Johnson, and Pfizer. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for anesthesia drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anesthesia drugs as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, AbbVie, Aspen Holdings, AstraZeneca, B. Braun Melsungen, Baxter, Eisai Company, Fresenius Se & Company, Hospira, Mylan NV, Piramal, and Roche. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for anemia drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anemia drugs as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Acceleron Pharma, Akebia Therapeutics, Amgen, Bayer, Biocon, bluebird bio, Bristol-Myers Squibb, Centocor Ortho Biotech Products, Eli Lilly and Company, GlaxoSmithKline, GlycoMimetics, and Regen BioPharma. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for allergy drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of allergy drugs as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Collegium Pharmaceutical, McNeil Consumer Healthcare, Meda Pharmaceuticals, Novartis Consumer Healthcare, and Schering-Plough. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for active barrier systems across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of active barrier systems as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include A-SAFE, Avon Barrier Corporation, Delta Scientific, FutureNet Group, Hill & Smith Holdings, Lindsay, NV Bekaert, Tata Steel, Trinity Industries, and Valmont Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for acoustic sensors across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of acoustic sensors as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include API Technologies, Asr&D, AVX, Boston Piezo-optics, Campbell Scientific, Canon, CeramTec, Cognizant, CTS, Dytran Instruments, ECS Inc. International, EPCOS, Epson Toyocom, Halliburton, Honeywell, Hubbell Lighting, Ifm Efector, Kyocera, Murata Manufacturing Company, PAI Technologies, Panasonic, Phonon Corporation, Pro-micron, Rakon, Raltron, Schlumberger, Senseor, SHOULDER Electronics, Siemens Process Instrumentation, TDK Corporation, Teledyne Microwave Solutions, Transense Technologies, TriQuint Semiconductor, and Vectron International. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

According to 99Strategy, the Global Antibody Drug Conjugate Market is estimated to reach xxx million USD in 2021 and projected to grow at the CAGR of xx% during the 2022-2027. The report analyses the global Antibody Drug Conjugate market, the market size and growth, as well as the major market participants. The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels.The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report. Key Regions Asia Pacific North America Europe South America Middle East & Africa Key Companies Seattle Genetics/Takeda Roche ImmunoGen Immunomedics Pfizer Celldex Therapeutics Millennium Pharmaceuticals Bayer HealthCare Mersana Therapeutics Heidelberg Pharma Oxford BioTherapeutics Takeda Pharmaceutical Company Limited Key Product Type Adcetris Kadcyl Other Market by Application Hospital Pharmaceutical Company Research Institutions Main Aspects covered in the Report Overview of the Antibody Drug Conjugate market including production, consumption, status & forecast and market growth 2017-2021 historical data and 2022-2027 market forecast Geographical analysis including major countries Overview the product type market including development Overview the end-user market including development ...

10/28/2021

x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT